Since our prior study demonstrated an interaction of FGFR4 with TRIP13 in the CRC cell lines, SW480 and HT29 [11], we sought to determine the downstream signalling pathways that lead to TRIP13‐driven CRCs by targeting TRIP13 with a small‐molecule inhibitor. The gene discussed is FGFR4; the disease is colorectal carcinoma.